Polaris Announces Dr. Chi Van Dang Joining its Scientific Advisory Board
Polaris Group, a biopharmaceutical company focused on developing novel drugs for cancer, announced that Chi Van Dang, M.D., Ph.D. has joined its Scientific Advisory Board…
Polaris Announces Drs. James Allison and Padmanee Sharma Joining its Scientific Advisory Board
Polaris Pharmaceuticals, Inc. (a subsidiary of Polaris Group), a biopharmaceutical company focused on developing novel drugs for cancer, announced that James Allison, Ph.D. and Padmanee Sharma, M.D., Ph.D. have joined its Scientific Advisory Board …
Polaris Group Announces Results of a Phase 1 Clinical Study with its Lead Therapeutic Candidate ADI‑PEG 20 in Metastatic Uveal Melanomas
SAN DIEGO, June 05, 2018 – Polaris Group, a biopharmaceutical company focused on developing novel drugs for cancer, announced results from a phase 1 clinical study that features Polaris lead therapeutic candidate ADI-PEG 20 in combination with pemetrexed and cisplatin (ADIPEMCIS) in first-line treatment for argininosuccinate synthetase (ASS1) deficient metastatic uveal melanomas…
Polaris Group Announces Results of a Phase 1 Clinical Study with its Lead Therapeutic Candidate ADI-PEG 20 in Combination with Pembrolizumab for Advanced Solid Tumors
SAN DIEGO, June 04 2018 – At the American Society Clinical Oncology’s 2018 annual meeting, scientists from National Institute of Cancer Research Taiwan reported results from a phase 1 clinical study, showing that Polaris lead therapeutic candidate ADI-PEG 20 in combination with pembrolizumab has activity for advanced solid tumors…
Polaris Group Presents Results for Phase 1 Clinical Study with its Lead Therapeutic Candidate ADI‑PEG 20 Plus FOLFOX in Hepatocellular Carcinoma
SAN DIEG0, June 03 2018 – Polaris Group announced results from a phase 1 clinical study, showing that Polaris lead therapeutic candidate ADI-PEG 20 in combination with FOLFOX demonstrated promising efficacy for heavily pre-treated hepatocellular carcinoma (HCC) patients…
Polaris Group Announces Treatment of First Patient in a Phase 2 Study of ADI‑PEG 20 Plus Gemcitabine and Docetaxel for Soft Tissue Sarcoma
SAN DIEGO, May 31, 2018 – Polaris Group announced today that the first patient has been dosed in a phase 2 trial of ADI‑PEG 20 in combination with gemcitabine and docetaxel for the treatment of soft tissue sarcoma, sponsored by Washington University…
Polaris Signs Collaboration Agreement with MD Anderson Cancer Center to Join its Immunotherapy Platform for Clinical Trials and Preclinical Research
SAN DIEGO, May 10, 2018 – Polaris Group announced that it has signed a multiyear strategic Collaboration Agreement with MD Anderson Cancer Center to utilize its Immunotherapy Platform, led by world-renowned immunotherapy pioneer Dr. James Allison, Dr. Padmanee Sharma, and Dr. Patrick Hwu, to design clinical studies and monitor biomarkers in immune functions associated with the therapies…
ADI‑PEG 20 and PD-1/PD-L1 Blockade Lead to Strong Anti-tumor Activity in ASS1- and PD-L1-negative Fibrosarcoma Murine Model
SAN DIEGO, March 26, 2018 – Polaris Group announced today that its lead product ADI‑PEG 20 modulates PD-L1 expression via stimulating the release of IFN-a and -b in several tumor cell lines and the combination of ADI‑PEG 20 and PD-1/PD-L1 blockade abrogated tumorigenesis in a murine model according to research presented by a group from Barts Cancer Institute, London …
Polaris Group’s ADI‑PEG 20 Shows Promising Clinical Activity in NSCLC When Combined with Standard First Line Chemotherapy Regimen
SAN DIEGO, January 10, 2018 – Polaris Group announced today that the combination of its lead therapeutic ADI‑PEG 20 (pegylated arginine deiminase) with the standard first-line chemotherapy cisplatin + pemetrexed doublet (PemCis) has shown promising clinical activity in an ongoing phase 1 study cohort of non-squamous non-small cell lung carcinoma (NSCLC) patients…
Polaris Announces Results of a Phase 2 Trial of ADI‑PEG 20 in Relapsed/Refractory or Poor-risk Acute Myeloid Leukemia
SAN DIEGO, September 12, 2017 – Polaris Group announced today that its lead therapeutic ADI‑PEG 20 (pegylated arginine deiminase) demonstrated a good safety profile and an efficacy signal as monotherapy in a phase 2 trial in relapsed/refractory or poor-risk acute myeloid leukemia (AML) patients, as reported in the journal Scientific…